Extracorporeal shockwave myocardial revascularization (ESMR) is a therapy for refractory angina pectoris. Our aim was to assess the efficacy and safety of ESMR in the management of patients with stable coronary artery disease (CAD) and heart failure as well as its effects on inflammation and angiogenesis. In this single-arm prospective trial, we included 48 patients with CAD, myocardial ischemia assessed by radionuclide imaging, echocardiographic evidence of left ventricular systolic dysfunction and without revascularization options. Changes in angina grading score, myocardial perfusion, left ventricular ejection fraction, and six-minute walk test after ESMR therapy were used for efficacy assessment. Changes of inflammation and angiogenesis biomarkers were also evaluated. ESMR therapy was performed using a commercially available cardiac shockwave generator system (Cardiospec; Medispec). After 9 weeks of ESMR therapy, a significant improvement was found regarding the initial angina class, severity of ischemia, left ventricular ejection fraction, and six-minute walk test in most patients. No deleterious side effects after treatment were detected. Regarding biomarkers, endothelial progenitor cells and angiopoietin-3 were significantly increased whereas IL-18 and TGF-β were significantly decreased after ESMR in the total group. Notably, VEGF, IL-1ß, and lipoxin A4 levels were significantly increased only in patients with myocardial ischemia improvement. In conclusion, ESMR therapy is safe and effective in most but not all patients with CAD and heart failure. ESMR is associated with increased markers of angiogenesis and decreased markers of inflammation. Myocardial ischemia improvement after ESMR is associated with increased markers of angiogenesis and pro-resolving mediators.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2020.12.065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ligation-assisted endoscopic submucosal resection following unroofing technique for small esophageal subepithelial lesions originating from the muscularis propria.
World J Gastroenterol
August 2024
Department of Gastroenterology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen 518020, Guangdong Province, China.
Background: The majority of esophageal subepithelial lesions originating from the muscularis propria (SEL-MPs) are benign in nature, although a subset may exhibit malignant characteristics. Conventional endoscopic resection techniques are time-consuming and lack efficacy for small SEL-MPs.
Aim: To evaluate the efficacy and safety of ligation-assisted endoscopic submucosal resection (ESMR-L) following unroofing technique for small esophageal SEL-MPs.
Efficacy of endoscopic submucosal resection with a ligation device for small rectal neuroendocrine tumor: study protocol of a multicenter open-label randomized control trial (BANDIT trial).
BMC Gastroenterol
February 2024
Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- Endoscopic resection is a common local treatment for small rectal neuroendocrine tumors, but there's no clear consensus on the best method, prompting a comparison of two techniques: ESD and ESMR-L.
- The study is a prospective, multicenter, randomized trial involving 266 patients, evaluating the effectiveness of ESMR-L versus ESD, with the main goal of determining if ESMR-L offers similar rates of complete tumor removal (R0 resection).
- This trial will also assess additional factors like procedure time, costs, and complications, contributing to understanding the best approach for treating these tumors.
Short-term outcomes of endoscopic resection for colorectal neuroendocrine tumors: Japanese multicenter prospective C-NET STUDY.
Dig Endosc
August 2024
Division of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan.
Article Synopsis
- The study examines the increasing incidence of colorectal neuroendocrine tumors (NETs) due to more frequent cancer screenings and colonoscopies, highlighting a shift in management from radical surgery to endoscopic resection methods.
- Researchers analyzed short-term outcomes from 418 patients who underwent endoscopic treatments for colorectal NETs, focusing on en bloc resection rates and tumor-free margins.
- The findings revealed that various endoscopic methods, particularly endoscopic submucosal resection with a ligation device (ESMR-L), were effective and safe for treating tumors smaller than 10 mm, with high R0 resection rates and minimal complications.
Efficacy of Endoscopic Resection for Rectal Neuroendocrine Tumors Smaller than 15 mm.
Dig Dis Sci
July 2023
Department of Gastroenterology and Hepatology, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Background: Local resection, including endoscopic resection, is recommended for rectal neuroendocrine tumors (NETs) < 15 mm in patients without risk factors for metastasis, though the short- and long-term outcomes are unclear.
Aims: This study investigates the efficacy of endoscopic resection for rectal NETs < 15 mm.
Methods: The short- and long-term outcomes of patients with rectal NETs < 15 mm who underwent endoscopic resection and the outcomes of each endoscopic technique were analyzed.
Multiple ligation-assisted endoscopic submucosal resection combined with endoscopic ultrasonography: a novel method to treat rectal neuroendocrine tumors.
Eur J Gastroenterol Hepatol
February 2023
Department of Digestive Diseases, 900TH Hospital of Joint Logistics Support Force.
Objective: The first choice of treatment for rectal neuroendocrine tumors (R-NETs) 10 mm in size is endoscopic resection, there is still controversy concerning the optimal endoscopic treatment for resecting R-NETs. This study evaluated the efficacy and safety of multiple ligation-assisted endoscopic submucosal resection combined with endoscopic ultrasonography (EMR-MLUS) for R-NETs.
Methods: We retrospectively analyzed the data of 62 patients with R-NETs ≤10 mm in size who underwent EMR-MLUS or ligation-assisted endoscopic submucosal resection combined with endoscopic ultrasonography (EMR-LUS) between May 2019 and April 2022, including tumor characteristics, endoscopic complete resection, pathological complete resection, the procedure time, adverse events, and follow-up were compared between the two groups of patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!